Study shows pharmacists knew more about penicillin allergy than MDs

If you have gone through life avoiding certain antibiotics because you think you're allergic to penicillin, you'd probably want to know if you're not actually allergic. A new study shows many physicians who treat patients with "penicillin allergy" listed in their charts may not fully understand important facts about penicillin allergy. They may not be aware penicillin allergy can resolve over time and they don't fully understand the importance of allergy testing to make sure a penicillin allergy currently exists.

The study in Annals of Allergy, Asthma and Immunology, the scientific publication of the American College of Allergy, Asthma and Immunology (ACAAI) examined 276 surveys completed by non-allergist physicians, physician assistants, nurse practitioners and pharmacists at Rochester Regional Health. They found more than 80 percent of the general practitioners surveyed in their system knew a referral to an allergist for testing is appropriate for someone with a reported penicillin allergy. Despite that, the physicians had either never referred their patients to an allergist, or had only done so with one patient a year. In addition, pharmacists surveyed in their system had a better overall understanding of penicillin allergy.

"We were not surprised pharmacists understood the course of penicillin allergy better than other clinicians, given more extensive pharmacology education," says infectious diseases pharmacist Mary Staicu, PharmD, lead author of the study. "Of those surveyed, 78 percent of pharmacists knew penicillin allergy can resolve over time. Only 55 percent of the remaining respondents (non-allergist physicians, physician assistants and nurse practitioners) did." The survey also showed a limited understanding among internists and general practitioners regarding the large numbers of people who report penicillin allergy but have never been tested." Most of the physicians surveyed had been in practice more than 10 years.

Between 10-20 percent of Americans believe they have a penicillin allergy. But previous research has found only 10 percent of those people are truly penicillin allergic. In other words, 9 out of 10 people who think they have penicillin allergy are avoiding it for no reason. Even in people with documented allergy to penicillin, only about 20 percent are still allergic ten years after their initial allergic reaction.

"Our research found a poor understanding of penicillin allergy among non-allergists," says allergist Allison Ramsey, MD, study co-author and ACAAI member. "This was not a surprising finding given the clinical experience of most allergists, but it does provide an excellent opportunity for education on the topic - not just for patients, but for all health care professionals."

People who are labeled penicillin allergic are often prescribed second-line antibiotics, which may have a higher risk of side effects and increased cost. "More than 90 percent of people labeled with a penicillin allergy can tolerate penicillin-based antibiotics," says Dr. Ramsey. "Our survey showed only 30 percent of physician survey respondents knew that. It's important that doctors understand the importance of confirming penicillin allergy. But it's even more important that those who carry the label be educated and tested."

An allergist can work with you to find out if you have a true drug allergy and determine what antibiotics are available for safe and effective treatment. If you're not allergic, you'll be able to safely use antibiotics that are often more effective, and less expensive.

Staicu ML, Soni D, Conn KM, Ramsey A.
A survey of inpatient practitioner knowledge of penicillin allergy at 2 community teaching hospitals.
Ann Allergy Asthma Immunol. 2017 May 20. pii: S1081-1206(17)30339-3. doi: 10.1016/j.anai.2017.04.023.

Most Popular Now

A need for bananas? Dietary potassium regulates ca…

Bananas and avocados - foods that are rich in potassium - may help protect against pathogenic vascular calcification, also known as hardening of the arteries. University ...

FDA awards 15 grants for clinical trials to stimul…

The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to...

Amgen and CytomX Therapeutics announce strategic c…

Amgen (NASDAQ:AMGN) and CytomX Therapeutics, Inc., (NASDAQ:CTMX) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The co...

Novartis and The Max Foundation transform pioneeri…

Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid...

Roche launches NAVIFY Tumor Board solution to prov…

Roche (SIX: RO, ROG; OTCQX:RHHBY), has announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-...

AbbVie and Bristol-Myers Squibb announce clinical …

AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational an...

Tagrisso granted breakthrough therapy designation …

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatm...

Pfizer launches novel programs to put important su…

Pfizer today unveils enhanced offerings to help patients manage their life with cancer. Pfizer Oncology Together is a first-of-its-kind program for patients taking Pfizer...

Novartis and UC Berkeley collaborate to tackle 'un…

Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pu...

Printed meds could reinvent pharmacies, drug resea…

A technology that can print pure, ultra-precise doses of drugs onto a wide variety of surfaces could one day enable on-site printing of custom-dosed medications at pharma...

Danish discovery can pave the way for more effecti…

More than 600,000 Danes are being treated with cholesterol lowering medicine. 98 per cent of them are treated with statins, which curb the body's own production of choles...

Amgen and Simcere announce strategic collaboration…

Amgen (NASDAQ: AMGN) and Simcere Pharmaceutical Group have announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. Th...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]